Highest-materiality recent filing
Acadia Healthcare Q2 revenue flat YoY; adjusted EPS $0.38 vs $0.83; updates FY guidance
Revenue $865.8M flat YoY; same-facility revenue flat, patient days +0.8%, revenue per patient day -0.8%.
Acadia subsidiary faces $105M jury verdict in retaliatory termination suit
San Diego jury awarded $35M compensatory and $70M punitive damages on May 12, 2026.
Acadia Healthcare annual meeting: directors elected, incentive plan and say-on-pay approved
Three Class III directors elected with >73M votes each: Cancelmi, Fucci, Harris.
Acadia Healthcare Q1 revenue up 7.6% to $828.8M; raises FY2026 guidance
Revenue $828.8M (+7.6% YoY); same-facility revenue +7.3%.
Todd Young resigns as CFO effective April 30, 2026; to join private equity-backed animal health company.
Acadia Healthcare appoints Dan Cancelmi to board; Wade Miquelon to retire at 2026 annual meeting
Daniel Cancelmi, former Tenet Healthcare EVP & CFO, appointed to Acadia's Board effective March 12, 2026.
Acadia Healthcare Q4 net loss $13.02/sh on $996M goodwill impairment; appoints new CEO
Q4 revenue $821.5M (+6.1% YoY); net loss $13.02/diluted share from $996.2M goodwill impairment.
CEO Christopher H. Hunter resigned and left Board effective Jan 20, 2026; no successor named.
Acadia Healthcare appoints former CEO Debra Osteen as CEO; Chris Hunter departs
Debra Osteen appointed CEO and Class I director effective January 20, 2026; previously served as CEO from 2018-2022.
Acadia Healthcare reaffirms 2025 revenue $3.28-3.30B, adj. EBITDA $601-611M, adj. EPS $1.94-2.04
Reaffirmed 2025 guidance at J.P. Morgan Healthcare Conference: revenue $3.28B-$3.30B.
Acadia Healthcare lowers 2025 guidance after actuarial review shows $49M PLGL expense increase
Adjusted EBITDA guidance reduced to $601-611M from $650-660M; adjusted EPS to $1.94-2.04 from $2.35-2.45.
Acadia Healthcare settles securities class action for $179M; no admission of liability
Settlement of $179M resolves St. Clair County ER Sys. v. Acadia Healthcare case with no admission of liability.
Acadia Q3 revenue $851.6M (+4.4% YoY), net income falls; cuts full-year guidance; COO resigns
Q3 net income $36.2M ($0.40 diluted) vs $0.74 prior year; adjusted EPS $0.72 vs $0.91.
Acadia Healthcare appoints Todd Young as CFO effective Oct 27, 2025
Todd Young, former Elanco Animal Health CFO, appointed as Acadia Healthcare CFO effective Oct 27, 2025.
Acadia Healthcare 2026 capex to drop at least $300M; Q3 same-facility patient days up 1.3%
Total 2026 capex expected to decline at least $300M from 2025 guidance of $600-$650M.
Acadia Q2 revenue $869M (+9.2%), adjusted EPS $0.83; CFO Dixon resigns, Sides interim
Q2 revenue $869.2M (+9.2% YoY); same-facility revenue +9.5% with 7.5% higher rev/patient day.
Four Class II directors elected: Bernhard 77.5M for, Grieco 71.9M, Kelly 75.6M, Waud 63.6M (broker non-votes 2.2M).
Acadia Healthcare Q1 revenue $770.5M, net income $8.4M, affirms FY2025 guidance
Revenue $770.5M, up 0.3% YoY from $768.1M; same-facility revenue +2.1%, patient days +2.2%.
Acadia Healthcare prices $550M 7.375% senior notes due 2033 to repay revolver
Issued $550M aggregate principal of 7.375% Senior Notes due March 15, 2033.
Acadia Healthcare enters $1.65B senior secured credit facility, extends maturities to 2030
New $1B revolver and $650M term loan, both due Feb 28, 2030; replaces $600M revolver and term loan due Mar 2026.
Acadia Healthcare Q4 2024 revenue $774.2M (+4.2%); adj. EPS $0.64; announces $300M buyback
Q4 net income $32.6M ($0.35 diluted EPS); adjusted income $59.2M ($0.64 diluted EPS).
Acadia Healthcare Q4 same-facility patient days +3.2% YoY, in-line with prior guidance
Same-facility patient days for Q4 2024 grew 3.2% year-over-year.
Acadia Q3 revenue $815.6M (+8.7%), adj. EPS $0.91; margins expand
Revenue $815.6M, up 8.7% YoY; adjusted EBITDA $194.3M, up 10.5% YoY (excl. provider relief funds).
Acadia Healthcare receives federal subpoenas over admissions, billing practices
Voluntary request from US Attorney's Office (SDNY) and grand jury subpoena from Western District of Missouri.
Acadia Healthcare Q2 revenue up 8.8% to $796M; adj. EPS $0.91 provides updated 2024 guidance
Revenue $796.0M (+8.8% YoY); same-facility revenue +8.3% (patient days +2.6%, revenue/patient day +5.6%).
Acadia Healthcare appoints Dr. Nasser Khan as COO; board declassified
Dr. Nasser Khan appointed COO effective June 30, 2024; base salary $515,000, target bonus 85%.
Acadia Healthcare Q1 revenue up 9.1% to $768.1M, adjusted EBITDA up 14.9%, affirms FY2024 guidance
Revenue $768.1M (+9.1% YoY); same-facility revenue +9.2%; net income $76.4M ($0.83 diluted EPS).
Acadia Healthcare Q4 2023 revenue up 10% to $742.8M; adj. EPS $0.85
Revenue $742.8M (+10.0% YoY); same-facility revenue +10.3%.
Acadia Healthcare adds $350M in incremental term loans under existing credit facility
Added $350M in aggregate principal amount of incremental term loans (Second Amendment Term A Loans) on Jan 18, 2024.
Acadia Healthcare Q3 net loss $217.7M on $394M legal charges; revenue up 12.5%
Revenue $750.3M, +12.5% YoY; same facility revenue +13.0%.
Acadia Healthcare settles New Mexico civil litigation for $400M, no admission of liability
$400M aggregate settlement to resolve three New Mexico state court cases; no admission of liability.
Acadia Healthcare appoints former AMA President Dr. Patrice A. Harris to Board
Board increased Class III directors from two to three; Dr. Harris fills vacancy effective Oct 26, 2023, term expiring 2026.
Acadia Healthcare makes progress toward settling three New Mexico lawsuits
Filed unopposed motion to stay bond posting and execution of judgment in Inman Litigation.
Acadia Healthcare Q2 revenue up 12.2%; raises FY2023 guidance; acquires Turning Point Centers
Revenue $731.3M, up 12.2% YoY; adjusted EPS $0.92 vs $0.79 GAAP.
Acadia Healthcare hit with $485M jury verdict in New Mexico lawsuit; intends to challenge
Jury awarded $80M compensatory and $405M punitive damages on July 7, 2023, in third of five lawsuits.
Acadia Healthcare appoints Brian Farley as EVP & General Counsel; Chris Howard to retire
Brian Farley appointed EVP & General Counsel, effective July 26, 2023; previously Chief Legal Officer at GoHealth.
Acadia Healthcare appoints Heather Dixon as CFO effective July 10; Duckworth steps down
Heather Dixon appointed CFO, effective July 10, 2023; previously CFO at Everside Health, SVP/CAO at Walgreens Boots Alliance.
Acadia Healthcare shareholders re-elect directors, approve incentive plan at annual meeting
Michael J. Fucci re-elected with 74.4M for, 12.3M against; Wade D. Miquelon with 65.7M for, 21.0M against.
Acadia Healthcare Q1 revenue up 14.2% to $704.3M; affirms FY 2023 guidance
Revenue $704.3M (+14.2% YoY); same-facility revenue +13.3% on 6.5% more patient days and 6.4% higher revenue per day.
Acadia Healthcare Q4 revenue up 13.8% to $675.3M; guides FY2023 adj. EPS $3.10-3.40
Q4 net income $61.1M ($0.67 diluted EPS); adjusted EPS $0.74, including $0.04 from CARES Act PRF.
Acadia Healthcare issues 2023 guidance at Investor Day; revenue $2.79B-$2.86B
Affirms 2022 guidance: revenue $2.58-2.60B, adj. EBITDA $595-605M, adj. EPS $3.00-3.10.
Acadia Q3 revenue $666.7M (+13.5% YoY); adj. EPS $0.86; narrows FY2022 guidance
Revenue $666.7M, +13.5% YoY; same facility revenue +10.2% on 6.9% revenue per patient day and 3.1% patient day growth.
Acadia Healthcare Q3 2022: revenue up 13.5%, adj. EPS $0.86, narrows FY guidance
Revenue $666.7M (+13.5% YoY); same-facility revenue +10.2% on 6.9% revenue/patient day and 3.1% patient day growth.
Acadia Healthcare Q2 revenue up 11.9% to $651.7M; raises 2022 guidance
Adjusted diluted EPS $0.91 vs $0.84 ex-PRF; net income $80.1M.
Acadia Healthcare appoints R. David Kelly as independent director
R. David Kelly elected as Class II director effective June 28, 2022, filling a board seat increase.
Acadia Healthcare annual meeting elects directors, approves say-on-pay and auditor
Jason R. Bernhard elected with 83,048,381 votes; William F. Grieco with 63,327,920; Reeve B. Waud with 46,059,659.
Acadia Healthcare Q1 revenue up 11.9% to $616.7M; reaffirms FY2022 guidance
Revenue $616.7M (+11.9% YoY); same-facility revenue +8.6% on 6.2% higher revenue per patient day and 2.2% more patient days.
Acadia Healthcare appoints Christopher Hunter as new CEO, effective April 11, 2022
Christopher Hunter named CEO and director; effective April 11, 2022; previously at Humana, TriZetto, BlueCross BlueShield.
Acadia Healthcare Q4 revenue $593.5M, adjusted EPS $0.81; guides 2022 rev $2.55-2.60B
Q4 revenue $593.5M, same facility +10.7%; adjusted EBITDA $156.1M.
Acadia CEO Debbie Osteen extends employment to March 31, 2022 for transition; $900K bonus
CEO Debbie Osteen to step down as CEO on date set by Board, but remains a director until term ends.
Appointment of Dr. Nasser Khan as Chief Operating Officer On May 23, 2024, Acadia Healthcare Company, Inc. (the “Company”) announced the appointment of Dr. Nasser Khan as the Chief Operating Officer of the Company, effective June 30, 2024.
Effective October 26, 2023, the Board of Directors (the “Board”) of Acadia Healthcare Company, Inc. (the “Company”) increased the number of Class III directors serving on the Board from two to three and elected Patrice A. Harris, M.D., M.A. to fill the vacancy created by the increase in the number of Class III directors.
On June 30, 2023, Acadia Healthcare Company, Inc. (the “Company”) appointed Brian Farley as the Executive Vice President and General Counsel of the Company, effective July 26, 2023.
Chris Howard, currently Executive Vice President, General Counsel and Secretary, will retire from his position effective July 26, 2023.
the Company announced that David Duckworth will resign as Chief Financial Officer, effective July 10, 2023.
On June 1, 2023, Acadia Healthcare Company, Inc. (the “Company”) appointed Heather Dixon as the Chief Financial Officer of the Company, effective July 10, 2023.
Effective June 28, 2022, the Board of Directors (the “Board”) of Acadia Healthcare Company, Inc. (the “Company”) increased the number of Class II directors serving on the Board from three to four and elected R. David Kelly to fill the vacancy created by the increase in the number of Class II directors.
appointed Christopher H. Hunter as the Company’s new Chief Executive Officer and as a member of the Board, effective April 11, 2022.
announced that Debbie Osteen, Chief Executive Officer and Director of the Company, will retire as Chief Executive Officer and that it was anticipated that Ms. Osteen’s retirement would be effective on January 31, 2022.
announced that Debbie Osteen, Chief Executive Officer and Director of the Company, will retire as Chief Executive Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings